Even with Washington hitting the pause button during the federal shutdown, this month’s GBG Report still surfaced 78 new non-dilutive funding opportunities, notices of special interest, and RFIs across the life sciences landscape. That’s a slimmer number than usual — no surprise given the slowdown — but the quality and strategic relevance of these opportunities remain strong.
As part of iBIO’s partnership with G2G Consulting, our members receive exclusive access to this report each month, along with a private consultation option during the GBG webinar. You can find the full November GBG Report on the iBIO website.
Highlights From This Month’s Report
BARDA leads several near-term deadlines, including the Agnostic Diagnostics mNGS solicitation(11/20), the Rapid Antibody Production RFI (12/4), and the BioTools Innovator Program for early-stage technology developers (12/1). Additional BARDA opportunities extend into early 2026, such as ReadyDetect, the Paratus Digital Health Accelerator, and funding for wearable biosensor technologies (1/15). Other notable openings include PCORI’s FY26 Cycle 1 PFA supporting retrospective comparative-effectiveness studies (LOI due 1/6) and the DoD SBIR Release 12, which encompasses topics ranging from shelf-stable nucleic acid synthesis reagents to CBRN sensing platforms (12/10). The report also covers new opportunities in women’s health, pediatric innovation, infectious disease, biomanufacturing, and small-business development.